Immutep logo

Immutep Share Price Today

(NASDAQ: IMMP)

Immutep share price is $1.79 & ₹155.67 as on 6 Mar 2025, 2.30 'hrs' IST

$1.79

-0.01

(-0.56%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Immutep share price in Dollar and Rupees. Guide to invest in Immutep stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Immutep, along with analyst recommendations, forecasts, and comprehensive financials.

Immutep share price movements

  • Today's Low: $1.75
    Today's High: $1.84

    Day's Volatility :4.79%

  • 52 Weeks Low: $1.66
    52 Weeks High: $3.34

    52 Weeks Volatility :50.22%

Immutep (IMMP) Returns

PeriodImmutep LtdSector (Health Care)Index (Russel 2000)
3 Months
-7.25%
3.7%
0.0%
6 Months
-30.35%
-2.8%
0.0%
1 Year
-34.43%
2.5%
0.0%
3 Years
-29.25%
12.9%
-11.6%

Immutep (IMMP) Key Statistics

in dollars & INR

Previous Close
$1.8
Open
$1.82
Today's High
$1.84
Today's Low
$1.7518
Market Capitalization
$265.4M
Today's Volume
$83.9K
52 Week High
$3.335
52 Week Low
$1.66
Revenue TTM
$4.9M
EBITDA
$-48.7M
Earnings Per Share (EPS)
$-0.21
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-30.45%

How to invest in Immutep Stock (IMMP) from India?

It is very easy for Indian residents to invest directly in Immutep from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Immutep stock in both Indian Rupees (INR) and US Dollars (USD). Search for Immutep or IMMP on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Immutep or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Immutep shares which would translate to 0.486 fractional shares of Immutep as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Immutep, in just a few clicks!

Returns in Immutep (IMMP) for Indian investors in Rupees

The Immutep stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Immutep investment value today

Current value as on today

₹70,517

Returns

₹29,483

(-29.48%)

Returns from Immutep Stock

₹34,432 (-34.43%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Immutep (IMMP)

-43%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Immutep Stock from India on INDmoney has decreased by -43% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Immutep

  • BlackRock Inc

    0.51%

  • Meridian Wealth Management, LLC

    0.27%

  • XY Capital Ltd

    0.11%

  • Susquehanna International Group, LLP

    0.08%

  • ABC arbitrage SA

    0.05%

  • PFG Investments, LLC

    0.04%

Analyst Recommendation on Immutep

Buy

    88%Buy

    11%Hold

    0%Sell

Based on 9 Wall street analysts offering stock ratings for Immutep(by analysts ranked 0 to 5 stars)

Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Immutep Stock (IMMP)

What analysts predicted

Upside of 430.73%

Target:

$9.50

Current:

$1.79

Insights on Immutep Stock (Ticker Symbol: IMMP)

  • Price Movement

    In the last 7 days, IMMP stock has moved down by -5.8%
  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 2.11M → 1.73M (in $), with an average decrease of 9.0% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -19.27M → -21.48M (in $), with an average decrease of 3.8% per quarter
  • IMMP vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 100.9%
  • IMMP vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 86.5%
  • Price to Sales

    ForIMMP every $1 of sales, investors are willing to pay $44.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

IMMP Immutep Financials in INR & Dollars

FY19Y/Y Change
Revenue
$97.1K
↓ 94.69%
Net Income
$-11.3M
↑ 27.65%
Net Profit Margin
-11.6K%
↓ 11155.46%
FY20Y/Y Change
Revenue
$5.2M
↑ 5255.8%
Net Income
$-9.3M
↓ 17.22%
Net Profit Margin
-179.9%
↑ 11460.11%
FY21Y/Y Change
Revenue
$3.0M
↓ 47.0%
Net Income
$-22.8M
↑ 122.02%
Net Profit Margin
-753.57%
↓ 573.67%
FY22Y/Y Change
Revenue
$119.8K
↓ 95.71%
Net Income
$-22.6M
↑ 7.72%
Net Profit Margin
-18.9K%
↓ 18152.94%
FY23Y/Y Change
Revenue
$2.4M
↑ 1957.72%
Net Income
$-26.8M
↑ 23.86%
Net Profit Margin
-1.1K%
↑ 17768.47%
FY24Y/Y Change
Revenue
$2.6M
↑ 9.59%
Net Income
$-28.4M
↑ 7.07%
Net Profit Margin
-1.1K%
↑ 26.17%
Q3 FY23Q/Q Change
Revenue
$1.8M
-
Net Income
$-19.3M
-
Net Profit Margin
-1.1K%
-
Q4 FY23Q/Q Change
Revenue
$2.1M
↑ 15.96%
Net Income
$-21.2M
↑ 10.14%
Net Profit Margin
-1.0K%
↑ 53.13%
Q2 FY24Q/Q Change
Revenue
$1.7M
↓ 17.98%
Net Income
$-21.5M
↑ 1.23%
Net Profit Margin
-1.2K%
↓ 235.57%
Q3 FY24Q/Q Change
Revenue
$1.7M
↑ 0.0%
Net Income
$-21.5M
↑ 0.0%
Net Profit Margin
-1.2K%
↑ 0.0%
FY19Y/Y Change
Profit
$-11.4M
↑ 123.54%
FY20Y/Y Change
Profit
$-10.3M
↓ 8.91%
FY21Y/Y Change
Profit
$1.4M
↓ 112.67%
FY22Y/Y Change
Profit
$-1.3M
↓ 199.74%
FY23Y/Y Change
Profit
$970.0K
↓ 176.27%
FY24Y/Y Change
Profit
$-25.0M
↓ 2711.31%
Q3 FY23Q/Q Change
Profit
$896.2K
-
Q4 FY23Q/Q Change
Profit
$1.1M
↑ 24.41%
Q2 FY24Q/Q Change
Profit
$-19.4M
↓ 1838.11%
Q3 FY24Q/Q Change
Profit
$-19.4M
↑ 0.0%
FY19Y/Y Change
Operating Cash Flow
$-10.6M
↑ 96.57%
Investing Cash Flow
$-28.8K
↑ 248.39%
Financing Cash Flow
$5.6M
↓ 56.46%
FY20Y/Y Change
Operating Cash Flow
$-7.5M
↓ 29.09%
Investing Cash Flow
$-13.3K
↓ 53.3%
Financing Cash Flow
$14.1M
↑ 155.57%
FY21Y/Y Change
Operating Cash Flow
$-13.5M
↑ 62.74%
Investing Cash Flow
$-11.9K
↓ 19.37%
Financing Cash Flow
$40.2M
↑ 157.25%
FY22Y/Y Change
Operating Cash Flow
$-21.3M
↑ 71.37%
Investing Cash Flow
$-16.1K
↑ 46.88%
Financing Cash Flow
$35.4M
↓ 4.47%
FY23Y/Y Change
Operating Cash Flow
$-24.1M
↑ 18.7%
Investing Cash Flow
$-55.6K
↑ 261.07%
Financing Cash Flow
$51.1M
↑ 51.1%
Q2 FY23Q/Q Change
Operating Cash Flow
$-5.6M
↓ 41.08%
Investing Cash Flow
$-7.9K
↑ 0.0%
Financing Cash Flow
$51.2M
↓ 165734.78%

Immutep Technicals Summary

Sell

Neutral

Buy

Immutep is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Immutep (IMMP) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Immutep Ltd logo
-8.21%
-30.35%
-34.43%
-29.25%
-17.13%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Immutep Ltd logo
NA
NA
NA
-0.26
-0.3
-0.2
NA
0.12
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Immutep Ltd logo
Buy
$265.4M
-17.13%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Immutep

Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Organization
Immutep
Employees
0
CEO
Mr. Marc Voigt
Industry
Health Technology

Management People of Immutep

NameTitle
Mr. Marc Voigt
CEO, MD, CFO, Chief Business Officer & Executive Director
Ms. Deanne Miller LLB
COO, General Counsel & Joint Company Secretary
Dr. Frederic Triebel M.D., Ph.D.
Chief Scientific Officer & Executive Director
Dr. Florian D. Vogl M.D., M.Sc., Ph.D.
Chief Medical Officer
Mr. Christian Mueller BBA, MSc.
Chief Development Officer
Mr. Stephan Winckels M.D., Ph.D.
Acting Chief Medical Officer
Ms. Indira Naidu
Joint Company Secretary

Important FAQs about investing in IMMP Stock from India :

What is Immutep share price today?

Immutep share price today stands at $1.79, Open: $1.82 ; Previous Close: $1.80 ; High: $1.84 ; Low: $1.75 ; 52 Week High: $3.34 ; 52 Week Low: $1.66.

The stock opens at $1.82, after a previous close of $1.80. The stock reached a daily high of $1.84 and a low of $1.75, with a 52-week high of $3.34 and a 52-week low of $1.66.

Can Indians buy Immutep shares?

Yes, Indians can invest in the Immutep (IMMP) from India.

With INDmoney, you can buy Immutep at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Immutep at zero transaction cost.

How can I buy Immutep shares from India?

It is very easy to buy Immutep from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Immutep (IMMP) be purchased?

Yes, you can buy fractional shares of Immutep with INDmoney app.

What are the documents required to start investing in Immutep stocks?

To start investing in Immutep, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Immutep Stock (IMMP)?

Today’s highest price of Immutep (IMMP) is $1.84.

Today’s lowest price of Immutep (IMMP) is $1.75.

What is today's market capitalisation of Immutep?

Today's market capitalisation of Immutep IMMP is 265.4M

What is the 52 Week High and Low Range of Immutep Stock (IMMP)?

  • 52 Week High

    $3.34

  • 52 Week Low

    $1.66

What are the historical returns of Immutep (IMMP)?

  • 1 Month Returns

    -8.21%

  • 3 Months Returns

    -30.35%

  • 1 Year Returns

    -34.43%

  • 5 Years Returns

    -17.13%

Who is the Chief Executive Officer (CEO) of Immutep ?

Mr. Marc Voigt is the current Chief Executive Officer (CEO) of Immutep.